Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Ultragenyx Pharmaceutical has a total shareholder equity of $353.8M and total debt of $878.4M, which brings its debt-to-equity ratio to 248.3%. Its total assets and total liabilities are $1.5B and $1.2B respectively.
Key information
248.3%
Debt to equity ratio
US$878.42m
Debt
| Interest coverage ratio | n/a |
| Cash | US$607.51m |
| Equity | US$353.83m |
| Total liabilities | US$1.18b |
| Total assets | US$1.54b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RARE *'s short term assets ($799.6M) exceed its short term liabilities ($285.0M).
Long Term Liabilities: RARE *'s short term assets ($799.6M) do not cover its long term liabilities ($899.5M).
Debt to Equity History and Analysis
Debt Level: RARE *'s net debt to equity ratio (76.6%) is considered high.
Reducing Debt: RARE *'s debt to equity ratio has increased from 0% to 248.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE * has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RARE * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.